Recruitment methods for united states Alzheimer disease prevention trials
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index; 2 of the 24 sources its claims cite were checked for support.
Abstract
There are no substantially effective treatments or preventatives for Alzheimer disease. The few prevention trials that were undertaken did not shown efficacy for the drugs tested; but, nevertheless, advanced prevention trials methods. We review past recruitment methods and discuss areas for improvement. Improvements in recruitment methods can enhance the likelihood for accurately demonstrating the efficacy of an effective drug. Effective therapeutics to prevent AD await discovery and proof.
Overview
CoChat Summary
TL;DR
This paper is a methods-focused review arguing that Alzheimer disease prevention trials need more proactive, registry-based recruitment, especially when trials require enriched samples or biomarker-positive participants. It concludes that large prebuilt registries and, in some settings, two-tier screening can make recruitment faster and more efficient.
Key findings
- Recruitment time is a major driver of trial duration; in the four prevention trials discussed, recruitment ranged from 1.75 years (GEM) to 2.5 years (GuidAge), 3.7 years (ADAPT), and over 4.5 years (PREPARE), while follow-up was about 5 years in all four trials.
- In the GEM trial using voter registration lists, 243,400 brochures were mailed, 14,603 telephone attempts were made, 12,186 (83.4%) contacts were successful, and 3,072 (25.4%) were enrolled; this was 1.3 enrolled participants per 100 brochures mailed.
- The paper states that Medicare lists cover over 95% of residents aged typically from 62 for women and 65 for men and older in a community, making them useful for demographically representative recruitment.
- The paper reports that recruiting by age and APOE ε4 carrier status would create a cohort with a relatively higher prevalence of positive Aβ biomarkers, about 70% using ADNI data.
Methods
- Narrative review of recruitment methods for U.S. Alzheimer disease prevention trials, comparing direct prevention trials with add-on/nested prevention trials and drawing on examples from other prevention areas.
- Uses published trial examples and registry-based recruitment cases, including ADAPT, GEM, GuidAge, PREPARE, WHI-MS, PREADViSE, and the use of Medicare and voter registration lists.
- Main analysis is qualitative and methodological: it contrasts recruitment strategies, discusses assumptions behind enriched/risk-concentration sampling, and argues for registry-based and two-step biomarker screening approaches.
Limitations
- The paper states that current prevention strategies are constrained because there are no documented, effective interventions to prevent Alzheimer disease and no such prior knowledge about whether current biomarkers must be positive for treatment response.
- It notes that many past prevention-trial designs did not model important processes or drug-specific effects and often relied on limited control of known risk factors plus randomization for unknown biases.
- Evident from the text: the article is a review and argument piece, not an empirical recruitment study of one trial program, so its conclusions about “what works” are based on prior trials and examples rather than new experimental comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 4 Not valid · 21 Not checked · 26 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The formidable challenges to preventing clinical and pathological AD include that the causes and compelling drug targets are not sufficiently known, despite the importance, intense focus, and highly developed science of the amyloid-|3 cascade (7).”
§ Recruitment methods for united states Alzheimer disease prevention trials > Background and overview
What the sources say
- Partly supportedcites [7] Golde, 2011, Anti-Aß Therapeutics in Alzheimer’s Disease: The Need for a Paradigm Shift, Neuron sourceExperimental — accuracy not yet measured
Our copy supports the 'causes' half: the Introduction (para. 1) states 'key aspects of AD pathogenesis remain enigmatic,' and 'Other therapeutic approaches' cites 'a lack of understanding regarding the mechanisms of neural injury' and 'uncertainty regarding the best targets for neuroprotection in AD,' plus unestablished Aβ–tau links that hinder 'identify[ing] druggable therapeutic targets.' But the blanket assertion that compelling drug targets are not sufficiently known overstates this source: the same paper says advances 'have provided sound rationale for the development of potentially disease-modifying AD therapies' targeting the suspected trigger, that the amyloid/anti-Aβ rationale 'has very strong scientific underpinnings,' and that failed trials 'were not definitive tests of the cascade hypothesis' ('Critiques of the Aβ aggregate hypothesis'). So the target uncertainty the paper describes is confined to tau, neuroprotective and downstream approaches, not to AD drug targets generally, and the citing 'despite the ... highly developed science of the amyloid-β cascade' framing runs against the source's position. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“Voter registration lists, maintained by states, not the Federal government, were used in the GEM prevention trial in similar ways to Medicare lists.”
§ Recruitment methods for united states Alzheimer disease prevention trials > Examples of registries used in previous prevention trials: Medicare and voter registration lists
What the sources say
- Not checked yetcites [15] DeKosky, 2008, Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial, JAMA source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Recruitment periods for the four prevention trials above ranged from 1.75 years in GEM, to 2.5 years in GuidAge, and 3.7 for ADAPT, and over 4.5 for PREPARE (table 1).”
§ Recruitment methods for united states Alzheimer disease prevention trials > Methodological considerations and current issues
What the sources say
- Not checked yetcites table 1
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Two prevention trials have employed Medicare lists in order to aid recruitment (14, 17).”
§ Recruitment methods for united states Alzheimer disease prevention trials > Examples of registries used in previous prevention trials: Medicare and voter registration lists
What the sources say
- Not checked yetcites [14] 2007, Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial, Neurology source
- Not checked yetcites [17] Sano, 2008, A multi-center, randomized, double blind placebocontrolled trial of estrogens to prevent Alzheimer’s disease and loss of memory in women: design and baseline characteristics, Clin
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus the recruitment periods represented about 30% to 90% of the followup periods.”
§ Recruitment methods for united states Alzheimer disease prevention trials > Methodological considerations and current issues
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 53 claims and to verify the 22 references still open.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Negative stigma around memory or other cognitive problems, and/or a caregiver's need for assistance may influence recruitment success in older adult populations, 17 particularly in minority, ethnic groups. 16”
From The efficacy of mindfulness-based cognitive therapy to improve depression symptoms and quality of life in individuals with memory difficulties and caregivers: A short report (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recruitment and retention issues with cognitively impaired populations are known. 15 , 16 , 17”
From The efficacy of mindfulness-based cognitive therapy to improve depression symptoms and quality of life in individuals with memory difficulties and caregivers: A short report (2022) · cites this paper as [17]
Experimental — accuracy not yet measured
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Alzheimer’s Dementia: Dilemmas in Clinical Research
(1985) · Humana Press eBooks · doi:10.1007/978-1-4612-5174-3 · Cited by 981
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
Berger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G., & Brown, D. L. (2006) · JAMA · doi:10.1001/jama.295.3.306 · Cited by 789
Plassman, B. L., Williams, J. W., Burke, J. R., Holsinger, T., & Benjamin, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00258 · Cited by 681
DeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 670
Cited by
Obstacles and opportunities in Alzheimer’s clinical trial recruitment
Watson, J. L., Ryan, L., Silverberg, N., Cahan, V., & Bernard, M. A. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1314 · Cited by 204
Facilitating Alzheimer Disease Research Recruitment
Grill, J. D., & Galvin, J. E. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000016 · Cited by 115
Langbaum, J., High, N., Nichols, J. B., Kettenhoven, C. L., Reiman, E., & Tariot, P. (2020) · The journal of prevention of Alzheimer's disease · doi:10.14283/jpad.2020.31 · Cited by 58
Langbaum, J. B. S., Karlawish, J. H., Roberts, J. S., Wood, E. M., Bradbury, A. R., High, N. M., Walsh, T. L., Gordon, D., Aggarwal, R., Davis, P., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.007 · Cited by 59
Rajji, T. K., for the PACt-MD Study Group, Bowie, C. R., Herrmann, N., Pollock, B. G., Bikson, M., Blumberger, D. M., Butters, M. A., Daskalakis, Z. J., Fischer, C. E., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200141 · Cited by 58
Metadata
- Authors
- Schneider, L. S.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Schneider, L.S.
- ORCID
- Schneider, L.S.
- Venue
- The Journal of nutrition, health and aging
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 16
- Issue
- 4
- Pages
- 331-335
- ISSN
- 1279-7707 (ISSN-L)
- PMC
- PMC12878103
- OpenAlex
- W2041339600
- Semantic Scholar
- ecc50beb7dcb6c629de126cf7b3c0b7508eb478b
- Cited by
- 22
- References
- 32
- Citations by year
- 2024: 2 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2014: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 4281 d)
- Locations
- The journal of nutrition health & aging (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Funders
- Australian Government
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- Alzheimer's disease, prevention trials, trial recruitment, drug efficacy, clinical trial design
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Research Design, United States, Biomarkers, Treatment Outcome, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recruitment methods for united states Alzheimer disease prevention trials. https://app.cochat.ai/papers/10.1007/s12603-012-0011-6
- The paper
- Schneider, L. S. (2012). Recruitment methods for united states Alzheimer disease prevention trials. The Journal of nutrition, health and aging. https://doi.org/10.1007/s12603-012-0011-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.